ance may differ materially from any future results or performance
expressed or implied by such statements. The important factors that could
cause our actual results or performance to differ materially include, among
others, risks associated with product discovery and development,
uncertainties related to the outcome and conduct of clinical trials
including unforeseen safety issues, uncertainties related to product
manufacturing, the lack of market acceptance of our products, our inability
to manage growth, the competitive environment in relation to our business
area and markets, our inability to attract and retain suitably qualified
personnel, the unenforceability or lack of protection of our patents and
proprietary rights, our relationships with affiliated entities, changes and
developments in technology which may render our products obsolete, and
other factors. Genmab is not under an obligation to up-date statements
regarding the future following the publication of this release; nor to
confirm such statements in relation to actual results, unless this is
required by law.
Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R);
HuMax-CD20(R); HuMax-EGFr(TM); HuMax-IL8(TM); HuMax-TAC(TM);
HuMax-HepC(TM); HuMax-CD38(TM); HuMax-CD32b(TM) and UniBody(R) are all
trademarks of Genmab A/S.
NOTE: PDL BioPharma and the PDL BioPharma logo are considered
trademarks of PDL BioPharma, Inc.
Contact:
Helle Husted,
Sr. Director, Investor Relations,
T: +45-33-44-77-30,
M: +45-25-27-47-13,
E: hth@genmab.com
Contact for PDL:
Kathleen Rinehart (Media)
+1-650-454-2543
kathleen.rinehart@pdl.com
Jean Suzuki (Investors)
+1-650-454-2648
jean.suzuki@pdl.com
Stock Exchange Release no. 09/2008
'/>"/>SOURCE Genmab A/S Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 Related biology technology :1.
Genmab and Pepscan to Identify Human Antibodies Against Intractable Targets2.
Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility3.
Medarex Announces Completion of Sale of Shares in Genmab A/S4.
Genmabs Financial Calendar for 20085.
Genmab Reaches Milestones in Ofatumumab Collaboration6.
Genmab Announces HuMax-CD32b Pre-Clinical Program7.
Roche Files IND for Second Genmab Antibody8.
Genmab A/S - R1507 Antibody to Enter Phase II Study to Treat Sarcoma9.
Genmab Announces Details of Planned Ofatumumab Phase II Study in Multiple Sclerosis10.
Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic11.
Genmab Announces Update on Recruitment of Patients in ofatumumab CLL Pivotal Study